Join PharmQD!

Become a member of our interactive community. Collaborate and network with your colleagues and trusted peers. Membership is free!

Communicate and Educate

Discuss new and important issues with your colleagues. Share your insights to help improve patient counseling.

Network With Peers

Join the conversation with trusted colleagues. Link up with professionals who share your ideas and insights.

Learn and Advance

Take free CE courses and rate courses for your peers. Find and apply for the newest jobs. Stay up-to-date on pharmacy news.

Unite

Share your experience with pharmacy students and technicians.

Create an account and receive access to the personalized box below, including your profile, bookmarks, friends, posts and more!

Join Now!

PharmNews

Featured News

Chronic Fatigue Syndrome Is in Your Gut, not Your Head - 06.28.2016

Physicians have been mystified by chronic fatigue syndrome; now, for the first time, Cornell University researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.More »

Featured News

Crisis in the Treatment of Osteoporosis - 06.23.2016

The remarkable progress made over the past 30 years to reduce fractures and dramatically improve the quality of life for millions of osteoporosis patients is rapidly being reversed, say two bone health experts.More »

Featured News

Experts Take Strong Stance on Testosterone Deficiency, Treatment - 06.22.2016

In an effort to address widespread concerns related to testosterone deficiency (TD) and its treatment with testosterone therapy, a group of international experts has developed a set of resolutions and conclusions to provide clarity for physicians and patients.More »

Featured News

Long-Term Opioids May Not Be Best Pain Management Option for All Sickle Cell Patients - 06.21.2016

In a small study looking at pain assessments in adults with sickle cell disease, researchers say overall, those treated long-term with opioids often fared worse in measures of pain, fatigue and curtailed daily activities than those not on long-term opioids.More »

Featured News

Study Compares Effectiveness of Weight-Loss Drugs - 06.15.2016

In an analysis that included nearly 30,000 overweight or obese adults, compared with placebo, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were each associated with achieving at least 5 percent weight loss at 52 weeks, and phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss, according to a study.More »

Advertisement

PharmTalk

New Blog Postings

Other Blog Posts

Ethics and the Pharmacist 04.19.15 2 comments nyrxman
Taking the Pulse of Pharmacy 03.18.15 nyrxman
Taking a "Shot" at Pharmacists? 03.07.15 2 comments michelerx1416
The Glass Is Half Full 02.18.15 1 comment nyrxman